RESEARCH ARTICLE

AJH | WILEY

Expression of p53 protein isoforms predicts survival in patients with multiple myeloma

Elizabeta A. Rojas[1,2] | Luis A. Corchete[1,2] | Cristina De Ramón[1] |
Patryk Krzeminski[1,2,3] | Dalia Quwaider[1,2] | Ramón García-Sanz[1,2,4,5] |
Joaquín Martínez-López[4,5,6,7] | Albert Oriol[5,8] | Laura Rosiñol[5,9] | Joan Bladé[5,9] |
Juan José Lahuerta[5,10] | Jesús F. San Miguel[4,5,11] | Marcos González[1,2,4] |
María Victoria Mateos[1,2,4,5] | Jean-Christophe Bourdon[12] |
Irena Misiewicz-Krzeminska[1,2,13] | Norma C. Gutiérrez[1,2,4,5]

[1]Hematology Department, University Hospital of Salamanca, IBSAL, Salamanca, Spain

[2]Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain

[3]Department of Nanobiotechnology and Experimental Ecology, Institute of Biology, Warsaw University of Life Sciences, Warsaw, Poland

[4]Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), CB16/12/00233, Salamanca, Spain

[5]Grupo Español de Mieloma (GEM), Barcelona, Spain

[6]Medicine Department, Complutense University, Madrid, Spain

[7]Spanish National Cancer Research Center (CNIO), Madrid, Spain

[8]University Hospital Germans Trias i Pujol, Barcelona, Spain

[9]Hospital Clinic of Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Barcelona, Spain

[10]Hematology Department, University Hospital 12 de Octubre, Madrid, Spain

[11]Clínica Universidad de Navarra, Centro de Investigaciones Médicas Aplicadas (CIMA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain

[12]School of Medicine, University of Dundee, Dundee, UK

[13]Experimental Hematology Department, Institute of Hematology and Transfusion Medicine, Warsaw, Poland

Correspondence
Norma C. Gutiérrez, Hematology Department, University Hospital of Salamanca, IBSAL, Paseo San Vicente, 58-182, Salamanca 37007, Spain.
Email: normagu@usal.es

Abstract

Loss and/or mutation of the *TP53* gene are associated with short survival in multiple myeloma, but the p53 landscape goes far beyond. At least 12 p53 protein isoforms have been identified as a result of a combination of alternative splicing, alternative promoters and/or alternative transcription site starts, which are grouped as α, β, γ, from transactivation domain (TA), long, and short isoforms. Nowadays, there are no studies evaluating the expression of p53 isoforms and its clinical relevance in multiple myeloma (MM). We used capillary nanoimmunoassay to quantify the expression of p53 protein isoforms in CD138-purified samples from 156 patients with newly diagnosed MM who were treated as part of the PETHEMA/GEM2012 clinical trial and investigated their prognostic impact.

Irena Misiewicz-Krzeminska and Norma C. Gutiérrez contributed equally to this study.

Quantitative real-time polymerase chain reaction was used to corroborate the results at RNA levels. Low and high levels of expression of short and TAp53β/γ isoforms, respectively, were associated with adverse prognosis in MM patients. Multivariate Cox models identified high levels of TAp53β/γ (hazard ratio [HR], 4.49; $p < .001$) and high-risk cytogenetics (HR, 2.69; $p < .001$) as independent prognostic factors associated with shorter time to progression. The current cytogenetic-risk classification was notably improved when expression levels of p53 protein isoforms were incorporated, whereby high-risk MM expressing high levels of short isoforms had significantly longer survival than high-risk patients with low levels of these isoforms. This is the first study that demonstrates the prognostic value of p53 isoforms in MM patients, providing new insights on the role of p53 protein dysregulation in MM biology.

1 | INTRODUCTION

Loss and/or mutation of the *TP53* gene are associated with short survival in multiple myeloma (MM). *TP53* mutations are uncommon at diagnosis, being present in less than 8% of cases, and deletion of the 17p13 chromosomal region, del(17p), has been identified in approximately 10% of newly diagnosed MM patients.[1,2] Although del(17p) has been routinely examined in the clinical setting for many years and *TP53* mutations are considered in present-day genetic studies, the p53 landscape covers a far wider range of phenomena than just *TP53* deletions and mutations.[3,4] Therefore, the study of other deregulations of the p53 pathway, particularly those that trigger defective p53 activity, are also important.[3–6]

The discovery of an alternative promoter in the *TP53* gene in 2005 led to the identification and characterization of p53 isoforms.[7] This finding has had a profound impact on our perspective on the p53 pathway and the ways of researching p53 tumor suppressor activity. The *TP53* gene expresses at least twelve p53 protein isoforms that are encoded by nine p53 mRNAs: TAp53α, TAp53β, TAp53γ, Δ40p53α, Δ40p53β, Δ40p53γ, Δ133p53α, Δ133p53β, Δ133p53γ, Δ160p53α, Δ160p53β, and Δ160p53γ proteins. The p53 isoforms arise from the combination of alternative promoter usage (proximal and internal promoters), alternative initiation codons (ATG1, ATG40, ATG133 and ATG160), and/or alternative splicing of introns 2 (Δ40) and/or 9 (α, β, γ) (Figures 1A and S6A,B). They can be grouped into subclasses or variants, such as the α, β, γ, from transactivation domain (TA), Δ40, and Δ133/Δ160 variants, based on the molecular mechanisms that lead to their formation (Figures S1D and S6A,B). The 12 p53 protein isoforms share a common region of the DNA-binding domain (DBD) but have different transactivation and oligomerization domains that allow them to differentially regulate the expression of p53 target genes and, at the same time, to be distinctively modulated by their negative regulators, like the Mdm2 and Mdm4 proteins.[7–11]

Several studies have demonstrated that p53 isoforms are differentially expressed in human cancers and that they affect the prognosis of some of these tumors. *TP53* deletions have been associated with low levels of p53 gene and protein expression in MM, using microarrays and immunohistochemistry, respectively.[3,12,13] Moreover, haploinsufficiency of p53 has been functionally demonstrated in MM cell lines[3] and a low level of expression of *TP53* gene has been associated with inferior outcome in MM patients. However, no studies have so far evaluated the expression of p53 isoforms and its clinical significance in MM.[8,14–16]

In this study, we investigated for the first time the relative expression of p53 isoforms in MM at the protein and mRNA levels. Using samples from homogeneously treated MM patients, we found that the differential expression of short and TA p53 isoforms influenced survival. In addition, incorporating expression levels of p53 isoforms improved the current cytogenetic-risk classification.

2 | MATERIALS AND METHODS

2.1 | Primary samples

A total of 156 protein samples from newly diagnosed MM patients enrolled in the clinical trial GEM2012 (NCT01916252) were included in the study. Although 458 patients were evaluated in this trial, fewer than 40% of the purified MM samples had sufficient material available to enable proteins and nucleic acids to be extracted. Details of the GEM2012 trial and sample processing have been previously reported.[17,18]

Baseline characteristics of patients for whom data were available are summarized in Table S1. No statistically significant differences between the present cohorts and the whole series from the GEM2012 trial ($N = 458$) were observed.

Fluorescence in situ hybridization (FISH) studies to detect *IGH* rearrangements, 17p and 1p deletions, and 1q gains were available for

all patients. Cytogenetic abnormalities were distributed as expected, based on previously published data. The high-risk cytogenetic group included those patients with t(4;14), t(14;16), and/or 17p deletion (del17p), according to International Myeloma Working Group criteria.[19] The median follow-up of the GEM2012 patients in this study was 72 months (range, 32–88 months). At the end of their follow-up, 68 patients (47%) had progressed, and 34 patients (23%) had died.

2.2 | Protein extraction and capillary electrophoresis immunoassay

Proteins were extracted simultaneously with genomic DNA and RNA by ice-cold acetone precipitation, as previously described.[20] The total protein assay was used to quantify protein concentration using WES™ system (ProteinSimple). Capillary electrophoresis immunoassay (CNIA) analysis, also called Simple Western, was performed using a WES

FIGURE 1 Schematic representation of human p53 protein isoforms, and the region containing the epitope for the p53 antibodies used in this study. (A) The main domains of p53 protein isoforms and their locations are represented by colors and amino acid (aa) numbering, respectively. The C-terminal sequences specific to the β (DQTSFQKENC) and γ (MLLDLRWCYFLINSS) variants are also shown. The molecular weight of each p53 isoform protein is indicated. The α, β, TA, long, and short protein isoforms are specifically recognized by A300-249A, KJC8, DO-1, and DO-11, respectively. (B) Number of MM patients with and without expression of each p53 isoform. (C) Number of MM patients with and without expression of TA isoforms, differentiating the two bands at 55–57 and 60–63 kDa that correspond to the TAp53α and TAp53β/γ isoforms, respectively. BR, basic region, aa 364–393 (yellow); DBD, DNA-binding domain, aa 101–292 (green); NLS, nuclear localization signal, aa 305–322 (orange); OD, oligomerization domain, aa 326–356 (red); PRD, proline-rich domain, aa 64–92 (blue); TAD1, transactivation domain 1, aa 1–42 (purple); TAD2: transactivation domain 2, aa 43–63 (violet) [Color figure can be viewed at wileyonlinelibrary.com]

machine (ProteinSimple, San Jose, CA) in accordance with the manufacturer's protocols and as previously described.[20,21] The primary antibodies used in the study were: mouse monoclonal DO-11 (BioRad; MCA1704, aa 181–190), whose epitope is present in the common region DBD and allows detection of all p53 protein isoforms; mouse monoclonal DO-1 (Santa Cruz Biotechnology; sc-126, aa 11–25), whose epitope is situated in the transactivation domain 1 that is present only in the TAp53α, TAp53β, and TAp53γ protein isoforms; rabbit polyclonal anti-p53 A300-249A-T (Bethyl Laboratories, Inc.; aa 375–393), which is specific to the α isoforms (TAp53α, Δ40p53α, Δ133p53α, and Δ160p53α); and anti-GAPDH (Cell Signaling; rabbit mAb #2118), which was used as the endogenous control. The rabbit polyclonal KJC8 antibody, which is specific to the β isoforms (TAp53β, Δ40p53β, Δ133p53β, and Δ160p53β), was provided by Prof. J-C. Bourdon (aa 331–341).[7]

All protein data were analyzed with Compass™ software (ProteinSimple), qualitatively at first, using the virtual blots (analogous to the images of the long-established western blot) that show the protein band with the expected size and also quantitatively, measuring the chemiluminescence peaks (peak area) that correspond to the expression of a particular protein. The protein expression was reported as relative to the endogenous control, GAPDH.

A more detailed protocol of the relative quantification of protein by CNIA has been reported previously.[18,20,21]

2.3 | Plasmids and transfection

We used the null-p53 JJN3 myeloma cells nucleotransfected with the specific expression vectors as positive controls for the p53α, p53β, p53γ, and Δ133p53α protein isoforms based on their migration profiles (Figure S1A–C). The commercial expression plasmids containing each isoform were obtained from Origene: p53β isoform (NM_001126114) SC322987, p53γ isoform (NM_001126113) SC322990, and Δ133p53α isoform (NM_001126115) SC322927. The pcDNA3 p53 WT, which codes for the canonical p53α, was a gift from David Meek (Addgene plasmid # 69003).[22] For transient protein expression, the null-p53 JJN3 myeloma cell line was nucleofected with 1 μg of each plasmid using the X005 program of the Amaxa II nucleofector (Lonza Bioscience). The proteins were collected 24 h post-transfection.

2.4 | Nucleic acid extraction and quantitative real-time polymerase chain reaction analysis

Total RNA was extracted from all samples using the AllPrep DNA/RNA Mini Kit (Qiagen). RNA integrity was assessed using Agilent 2100 Bioanalyzer (Agilent Technologies), and samples with an RNA integrity number (RIN) ≥ 6 were used. Total RNA (200 ng) was reverse-transcribed to cDNA using the SuperScript First-Strand Synthesis System, which uses oligo (dT) (Thermo Fisher). *TP53* isoforms (α, β, short [Δ133/Δ160] and long [TA/Δ40] isoforms) (Figure S6A,B)

were examined by quantitative real-time polymerase chain reaction (qRT-PCR), as previously described.[23] We also measured the expression of the *TP53* gene, detected at a region of mRNA common to all isoforms. The *PGK1* gene was used as the endogenous control. Samples with a Ct value ≥35 were considered as not expressed. Values of ΔCt, defined as Ct (housekeeping gene) − Ct (target gene), were also calculated.

2.5 | Next-generation sequencing

Genomic DNA samples were purified before sequencing using Genomic DNA Clean & Concentrator TM-10 (Zymo Research, Irvine, CA). Generation of libraries was carried out by target enrichment SeqCap EZ Choice gene panel (Roche NimbleGen Inc., Madison, WI) that included the coding sequence of *TP53* gene, which was designed by NimbleDesign platform. The resulting pool (48-plex) underwent high-throughput paired-end (101 bp) sequencing on an Illumina MiSeq System with 1500-fold coverage. Sequence alignment and variant calling was performed using MiSeq Reporter software (Illumina Inc.). Annotation of resulting variant call files (.vcfs) was performed with BaseSpace Variant Interpreter software, filtering out single nucleotide variants (SNVs) and small insertions/deletions with <100X reads and variant allele frequency (VAF) of < 10%.

2.6 | Statistical analysis

All statistical analyses were carried out with IBM SPSS Statistics 26.0 (IBM Corp., Armonk, NY), the Simfit package (W.G. Bardsley, University of Manchester, Manchester, UK; v7.0.9 Academic 32 bit), and R work packages. The Mann–Whitney *U* test was used to analyze the continuous variables.

For survival analyses, probabilities of overall survival (OS) and survival without progression (abbreviated to TTP) were assessed for each isoform using the Kaplan–Meier estimator. Patients who were not enrolled in the GEM2014 maintenance protocol after completing the GEM2012 clinical trial and who had not progressed, relapsed, or died were excluded from these analyses. The TTP was defined as the time from MM diagnosis to the day of disease progression. The survival curves of the isoform groups were compared using the log-rank test. The Cutoff Finder R package was used to determine the optimal cutoff for all survival analyses, which was defined as the most significant split discriminating between long and short survival when testing all possible cutoffs using the log-rank test.

After checking that the assumptions of proportional hazards held using Schoenfeld residuals and that there was no significant multicollinearity, multivariable Cox regression models were fitted considering a set of covariates with clinical and biological interest. Thus, the models included conventional covariates such as high-risk cytogenetics, age at diagnosis (years), International Staging System (ISS) stage (III vs. I/II), elevated lactate dehydrogenase (LDH), plasmacytoma occurrence, and protein isoforms expression previously

dichotomized by the Cutoff Finder R package. All these predictor covariates were entered into the regression equation together. These multivariable analyses were performed in R with the survival and car packages and associated forest plots were depicted using the survminer package. The relative contribution of the covariates to the Cox models was assessed by estimation of the proportion of the χ^2 statistic accruing from each covariate using the rms package; the higher the value of the statistic, the greater the contribution of the covariate to the model.

3 | RESULTS

3.1 | Expression patterns of p53 protein isoforms in MM

The expression of the p53 protein isoforms, α isoforms (TAp53α, Δ40p53α, Δ133p53α, and Δ160p53α); β isoforms (TAp53β, Δ40p53β, Δ133p53β, and Δ160p53β); TA isoforms (from transactivation domain: TAp53α, TAp53β, and TAp53γ); long (includes TA and Δ40: TAp53α, TAp53β, TAp53γ, Δ40p53α, Δ40p53β, and Δ40p53γ) and short isoforms (Δ133 and Δ160: Δ133/Δ160 α, β, and γ), as well as the total p53 protein, was assessed in the 156 MM samples by capillary nanoimmunoelectrophoresis using the specific antibodies (Figures 1A and S1A–D, Table S2).

The qualitative analysis of CNIA assays showed expression of the total p53 protein in 119/156 (76%) MM samples using the DO-11 antibody, which recognizes identical epitopes present in all the p53 protein isoforms. Based on the migration profile and the recognition pattern of this antibody, we observed that the major proportion of the total p53 protein corresponded to the long isoforms, which were detected in 112 of the 156 MM samples (72%), and the minor proportion corresponded to the short isoforms, which were only present in 28 of the 156 MM samples (18%) (Figure 1B).

The TA protein isoforms were detected in 128/151 MM samples (85%) using the DO-1 antibody, whose epitope is present in the transactivation domain 1 (TAD1, aa 20 to 25) (Figure 1A). Among the TA isoforms, we were able to distinguish the TAp53α band at 60–63 kDa in 90/151 (60%) samples, and the bands corresponding to TAp53β and TAp53γ, which were observed merged as a single band at 55–57 kDa in 71/151 MM samples (47%). Twenty-three patients (15%) did not show any of those isoforms (Figure 1C). The α and β protein isoforms were identified in 132/156 (85%) and 81/156 (52%) samples, respectively, as measured by the antibodies A300-249A and KJC8, which were specific to each isoform (Figure 1B).

The quantitative analysis revealed a high level of variability in the expression of all the p53 protein isoforms analyzed (Figure S1E). The expression of long isoforms was the most homogeneous, while the TAp53β/γ and α isoforms showed the greatest variability, as indicated by their higher coefficients of variation (Figure S1F).

3.2 | Relationship between p53 protein isoforms and cytogenetic abnormalities

We next analyzed the association between the expression of p53 protein isoforms and the cytogenetic features of MM patients. We found no statistically significant differences in the level of expression of total p53 protein between MM patients with and without del(17p). In contrast, we detected significant differences in the expression of long and TAp53β/γ isoforms between the two groups (Figure 2). We also noticed that none of the 14 patients with del(17p) expressed short isoforms (Figure 2). The expression of α and β protein isoforms was similar in all patients, irrespective of the presence of del(17p). The analysis considering the mutation status of TP53 showed comparable results. We found that the expression levels of TA isoforms were significantly higher in patients with mutated TP53 gene than in those with nonmutated gene. No significant associations between the expression of the other p53 protein isoforms and the presence of TP53 mutations were found (Figure S2).

On the other hand, no differences in the expression of any of the p53 protein isoforms analyzed and the total p53 protein were found to be associated with the presence of the gain of 1q, del(1p) or t(4;14). Since the limited number of patients with specific high-risk cytogenetic abnormalities may preclude the identification of significant differences, we also analyzed the relationship between the levels of p53 protein isoforms and cytogenetic alterations, grouping them into high- and standard-risk categories. We found statistically significant differences in the expression levels of TAp53β/γ isoforms between the two cytogenetic groups. High-cytogenetic-risk patients expressed TAp53β/γ isoforms significantly more strongly than did standard-risk patients (Figure 2). No differences in the expression of the other p53 isoforms and total p53 protein were found in either cytogenetic-risk group.

3.3 | Effect of the expression of p53 protein isoforms on MM patient survival

High levels of the short p53 isoforms were accompanied by a reduction of 75% (HR = 0.25, p = .004) in the risk of progression and an 88% (HR = 0.124, p = .014) drop in the risk of mortality (Figure 3A). Conversely, high levels of TA isoforms were associated with shorter TTP and OS (HR = 2.02, p = .008 and HR = 2.39, p = .018, respectively) (Figure S3A). Nevertheless, only the high level of expression of TAp53β/γ isoforms, but not of TAp53α, was associated with negative effects on TTP and OS (HR = 3.58, p < .001 and HR = 2.38, p = .022, respectively) (Figures 3B and S3B). The expression levels of α and β variants, as well as levels of total p53 protein had no influence on the survival of MM patients (Figure S3C).

We further explored the impact of expression levels of p53 protein isoforms on the survival of MM patients according to the cytogenetic abnormalities. In the present cohort, MM patients bearing at least one high-risk cytogenetic lesion, as well as those with the 17p deletion, had significantly shorter survival than those patients without these abnormalities, as described in previous studies (Figure S4A).

FIGURE 2 Association of p53 protein isoforms with deletion of 17p and with standard and high cytogenetic risk. Distribution of the expression of total p53 protein, long, TAp53β/γ and short isoforms, based on the presence or absence of the 17p deletion. Expression levels of the TAp53β/γ in MM patients with standard and high cytogenetic risk. The statistically significant differences between groups were determined by the Mann–Whitney U test (p values indicated) [Color figure can be viewed at wileyonlinelibrary.com]

When the cytogenetic-risk groups were analyzed with respect to the expression of p53 isoforms two different survival categories were identified within the high-risk group. Thus, MM patients with high-risk cytogenetics and a high level of expression of short p53 isoforms had significantly longer TTP and OS, which were comparable to those attained by standard-risk patients (Figure 4A). However, the effect of the TAp53β/γ isoforms, and long isoforms were the opposite, in such way that MM patients with high-risk cytogenetics and low-level expression of TAp53β/γ or long isoforms had longer TTP and OS, similar to those patients with standard risk as demonstrated by FISH (Figures 4B and S4B). These results indicate that high levels of short isoforms, and low levels of TAp53β/γ and long protein isoforms allow

the identification of a subset of MM patients with high cytogenetic risk that showed a better prognosis than expected. Interestingly, a positive influence of the short p53 isoforms was also observed when t(4;14) or del(17p) were considered separately (Figure S5A). Furthermore, within the MM cases with t(4;14) the high levels of expression of TAp53β/γ and long p53 isoforms distinguished a group of patients with significantly shorter TTP and OS (Figure S5B).

In the full multivariate Cox model for TTP, including p53 protein isoform expression and the conventional variables of proven prognostic impact on MM, we observed that high-risk cytogenetics and high expression levels of TAp53β/γ isoforms remained independent prognostic factors (HR = 4.49, p < .001 and HR = 2.69, p < .001,

FIGURE 3 Probability of survival without progression and of overall survival of MM patients by level of p53 protein isoforms. (A) TTP and OS probabilities in patients with high levels of short isoforms. (B) TTP and OS probability according to the expression of TAp53β/γ isoforms. The log-rank (Mantel–Cox) test p values are shown. MM, multiple myeloma; OS, overall survival; TA, transactivation domain; TTP, survival without progression [Color figure can be viewed at wileyonlinelibrary.com]

respectively). High-risk cytogenetics and the age at diagnosis retained their independent value in predicting adverse OS (Figure 4C). The analysis of the contribution of the variables showed that high-risk cytogenetics explained 28% and 44% of the variation in TTP and OS, respectively. Significantly, the expression levels of TAp53β/γ isoforms explained 41% of the variation in TTP (Figure S5C).

3.4 | Expression patterns of p53 isoforms at the mRNA level in MM

mRNA was available from 109 of the 156 MM samples. We quantified the p53 isoforms by qRT-PCR using a well-established approach,[23] selecting the p53 mRNA variants that were homologous with those identified at the protein level by CNIA, that is to say, the α, β, short

(Δ133/Δ160), and long (TA/Δ40) isoforms (Figure S6A,B). The main limitation of this approach is the difficulty to quantify each specific isoform individually.[23] Therefore, our analysis of mRNA isoforms was limited to identifying the group of six long isoforms and the three TA isoforms were not distinguished. We also measured the expression of the *TP53* gene, detected at a region of mRNA common to all isoforms. Samples with a Ct value ≥35 were considered as not expressed.

The *TP53* gene and α isoforms were expressed in all the 109 MM samples. The long isoforms were only absent from one MM sample, while the short isoforms were the least frequently expressed, only in 72/109 (67%) MM samples, similar to the p53 protein isoforms levels (Figure S6C). We wondered whether the low expression of the short isoform detected in our cohort could be corroborated in another set of MM patients. We took advantage of the availability of RNA-Seq data from 780 MM patients included in the MMRF CoMMpass trial

FIGURE 4 Probability of survival without progression and of overall survival of MM patients by cytogenetic risk and level of p53 protein isoforms, simultaneously. Analysis of MM patients with standard and high cytogenetic risk in combination with high and low expression levels of short (A) and TAp53β/γ (B) protein isoforms. The log-rank (Mantel–Cox) test *p* values are shown. (C) Forest plot of multivariate models with probabilities for each factor associated with TTP and OS of patients, based on the expression level of the studied p53 protein isoforms and age at diagnosis (years), ISS III versus I/II, high-level LDH, plasmacytoma and high versus standard cytogenetic risk (N = 145). 95% Confidence intervals are indicated in parentheses. MM samples with missing values were excluded from the model. ISS, International Staging System; LDH, lactate dehydrogenase; MM, multiple myeloma; TA, transactivation domain; TTP, survival without progression [Color figure can be viewed at wileyonlinelibrary.com]

(NCT01454297) to address this question. Even using a different approach to quantify mRNA, such as RNA-Seq, we observed that the number of MM patients expressing short mRNA isoforms was significantly lower than that expressing long mRNA isoforms (Figure S6D).

The univariate survival analysis using qRT-PCR data from mRNA revealed similar results to those observed at the protein level. MM patients with high levels of short isoform expression had statistically significant longer TTP and OS (median not reached) compared with patients with lower levels (HR = 0.50, p = .021 and HR = 0.31, p = .005, respectively) (Figure S6E). However, unlike p53 protein, the low levels of the *TP53* gene were associated with a shorter OS (HR = 0.27, p < .001) but had no impact on the TTP of MM patients (Figure S6F). Nevertheless, the expression of the α and β isoforms did not affect the survival of patients, similarly to what was noted at the protein level.

4 | DISCUSSION

We have investigated for the first time the expression of p53 isoforms at the protein and mRNA levels and analyzed their putative impact on the outcome of a large cohort of homogeneously treated MM patients. Currently, most of the information regarding expression of p53 isoforms in tumors is based on mRNA levels quantified by reverse transcription PCR. In fact, the quantification of p53 isoforms using classical western blot assays would need a significant amount of protein, which is not available for most of the cases. Our previous implementation of the capillary nanoimmunoassay platform for protein quantification in the clinical setting[18,20] allowed us to explore the hitherto unknown general landscape of p53 protein isoform expression in MM. Although this technology is highly effective analyzing low protein amounts, the genetic studies included in the evaluation of MM patients at diagnosis consume the entire sample in many cases.

We found total p53 protein to be expressed in more than 70% of MM samples, with the greater contribution of long than short isoforms, the latter being detected in very few samples. The TA protein isoforms were also expressed in most patients. Although qRT-PCR was able to detect expression of *TP53* gene in all the MM patients, and of p53 mRNA isoforms in the majority of cases, short mRNA isoforms were the least frequently expressed subclass, as observed at the protein level.

The short isoforms, also known as N-terminally truncated variants (the Δ133 and Δ160 variants), lack the first 132 amino acids, including a small part of the DBD. The integrity of the DBD is essential to the transcriptional factor functions of TAp53α, through which it can bind to the p53 DNA consensus recognition element (RE) present in the promoters of its target genes.[24,25] The absence of TAD1, TAD2, and a portion of the DBD from the short protein isoform structure entails the lack of sensitivity to proteasomal degradation and the absence of specific transactivation activity that characterize the TAp53α isoform. The Δ133p53α isoform not only is defective in promoting apoptosis, but also acts dominant-negatively toward TAp53α, inhibiting p53-mediated apoptosis.[7] Some studies have shown abnormal expression of short mRNA isoforms in tumor cells relative to normal tissues. In addition, a negative impact of the short mRNA isoforms on the

outcome of oncological patients has also been reported.[7,26–33] In contrast to these findings, we observed a significant positive influence on MM patient prognosis of a high level of expression of the short p53 isoforms, quantified at the protein or mRNA level. However, the impact of the short isoforms on prognosis differs depending on the tumor type. For example, the Δ133p53β expression has been associated with adverse prognosis in breast cancer,[27] while with better prognosis in mutant p53 ovarian cancer.[28,31] Recently, the co-expression of the p53 isoforms has been shown to differentially regulate the p53-POLι-dependent DNA damage tolerance (DDT) pathway.[34] However, since only 12 MM patients with co-expression of TAp53α and short isoforms were identified, we can speculate that, in this particular cancer, it is less likely that the short isoforms are affecting the DDT pathway. Accordingly, it can be said that there is little information about the quantification of short isoforms in hematological cancers, and their functions are not completely understood.

The TA isoforms (TAp53α, TAp53β, and TAp53γ) possess the entire N-terminal domain, which contains the two independent trans-activation domains (TAD1 and TAD2), but a different C-terminal. TAp53α, which is the canonical p53 protein and the most abundant p53 isoform, contains the complete C-terminal region, including the oligomerization domain (aa 326–356) and the basic domain (aa 364–393), but the TAp53β and TAp53γ isoforms are C-terminally truncated variants. These structural differences determine their differential functions. Our cohort featured a higher level of expression of TAp53α than of TAp53β/γ proteins. We also noted a negative impact of the high level of expression of TAp53β/γ proteins on the survival of MM patients. These data are consistent with another study of acute myeloid leukemia patients in which high levels of TAp53α and low levels of TAp53β/γ were associated with a greater sensitivity to valproic acid treatment.[35] Elevated TAp53γ mRNA levels have also been associated with reduced progression-free survival in uterine serous carcinoma.[36] However, opposite results showing an association between low levels of TAp53β and TAp53γ mRNAs and worse prognosis have also been reported.[14,37] In more than 10 years of intensive research, several studies have displayed the differential and aberrant expression of C-terminally truncated variants in various cancers. Nonetheless, their properties remain controversial, as shown in several apparently contradictory reports[7,14–16,26,38–40] that do not provide enough and clear evidence for defining the TAp53β/γ functions. For example, a significant increase in p21 and BAX promoter activities was found to be enhanced by overexpression of the TAp53α isoform, but not by the overexpression of TAp53β and TAp53γ.[41] Moreover, an *in vivo* study revealed that the TAp53β and TAp53γ isoforms significantly increased the tumor growth of H1299 cells.[42] Although the discrepancies among these studies cannot easily be explained, it seems most plausible that the functions of the TAp53β and TAp53γ isoforms are dependent on the cellular and tissue context.

It was of particular note that considering the expression levels of p53 isoforms made it possible to refine the prognostic significance of the cytogenetic-risk classification. Thus, high-cytogenetic-risk patients who expressed low levels of short p53 isoforms or high levels of TA/long p53 isoforms had shorter survival than expected, while the survival of the group of high-cytogenetic-risk patients expressing high levels of short

p53 isoforms or low levels of TA/long p53 isoforms was comparable to that of patients with standard cytogenetic risk. These results were also observed when each of the high-risk cytogenetic alterations was analyzed in conjunction with the expression of p53 protein isoforms.

In conclusion, short and TAp53β/γ protein isoform expression is associated with the clinical outcome of MM patients, and the prognostic stratification of MM patients is notably improved when cytogenetic risk is combined with their expression levels. These novel findings broaden the spectrum of the known actions of the p53 protein affecting MM outcome beyond the well-known unfavorable prognosis of deletions and/or mutations of the *TP53* gene.

CONFLICT OF INTERESTS

Dr García-Sanz reports receiving personal fees from Amgen, Janssen, Takeda, and Pfizer, and receives honoraria from Pharmacyclics, research funding from Hospira, and travel accommodation from Celgene, unconnected with the submitted work. Dr Martínez-López has consulting and advisory roles with Novartis, Celgene, Janssen, and Bristol-Myers Squibb, receives speakers' bureau compensation from Novartis, Celgene, Janssen, and Bristol-Myers Squibb, and receives research funding from Novartis, Celgene, Janssen, and Bristol-Myers Squibb (institutional). Dr Oriol has consulting and advisory roles with Amgen and Janssen-Cilag, Amgen, and receives research funding from Janssen (institutional). Dr Bladé receives honoraria from Celgene, Janssen, and Amgen. Dr Lahuerta has consulting and advisory roles with Janssen-Cilag and Celgene. Dr San Miguel has consulting and advisory roles with Amgen, Bristol-Myers Squibb, Celgene, Janssen, MSD, Novartis, Takeda, and Roche. Dr Rosiñol receives honoraria from Janssen, Celgene, Amgen, Takeda, Sanofi, GSK, and Karyofarm. Dr Mateos receives honoraria and speakers' bureau compensation from Janssen and Celgene, Onyx, Takeda, Novartis, and Bristol-Myers Squibb, unconnected with the submitted work. Dr Gutiérrez receives honoraria from Janssen unconnected with the submitted work. The other authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS

Elizabeta A. Rojas conceived the idea and designed the study, developed, and performed qRT-PCR and CNIA experiments, analyzed data, prepared the figures and wrote the manuscript; Luis A. Corchete analyzed the clinical data, supervised the statistical analysis and participated in the preparation of figures; Cristina De Ramón performed next-generation sequencing experiments, analyzed the clinical data, and participated in the preparation of tables; Patryk Krzeminski carried out the nucleofection assays for generation of positive controls; Dalia Quwaider assisted with laboratory experiments; Ramón García-Sanz, Joaquín Martínez-López, Albert Oriol, Laura Rosiñol, Joan Bladé, Juan José Lahuerta, Jesús F. San Miguel, Marcos González, María Victoria Mateos, and Norma C. Gutiérrez provided patient samples and clinical data and were responsible for obtaining informed consent from patients. Jean-Christophe Bourdon provided antibodies, contributed to the data interpretation, and provided support with conceptual issues; Irena Misiewicz-Krzeminska designed the study, developed and performed CNIA experiments, analyzed protein data, prepared figures, and supervised the whole study; Norma C. Gutiérrez conceived the idea and designed the study, participated in the writing of the manuscript, supervised the whole study, and provided funding. All authors reviewed critically and approved the manuscript.

DATA AVAILABILITY STATEMENT

All data generated during this study are included in this published article and its supplementary information files. The raw data analyzed during the current study available from the corresponding author on reasonable request.

ORCID

Elizabeta A. Rojas https://orcid.org/0000-0002-2541-7254
Luis A. Corchete https://orcid.org/0000-0003-4577-8599
Cristina De Ramón https://orcid.org/0000-0002-8167-6410
Patryk Krzeminski https://orcid.org/0000-0002-0526-9135
Joaquín Martínez-López https://orcid.org/0000-0001-7908-0063
Irena Misiewicz-Krzeminska https://orcid.org/0000-0002-4206-8586
Norma C. Gutiérrez https://orcid.org/0000-0001-5834-9510

REFERENCES

1. Lodé L, Eveillard M, Trichet V, et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. *Haematologica*. 2010; 95(11):1973-1976. doi:10.3324/haematol.2010.023697

2. Cardona-Benavides IJ, de Ramón C, Gutiérrez NC. Genetic abnormalities in multiple myeloma: prognostic and therapeutic implications. *Cells*. 2021;10(2):336. doi:10.3390/cells10020336

3. Teoh PJ, Chung TH, Sebastian S, et al. p53 Haploinsufficiency and functional abnormalities in multiple myeloma. *Leukemia*. 2014;28(10): 2066-2074. doi:10.1038/leu.2014.102

4. Shah V, Sherborne AL, Walker BA, et al. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. *Leukemia*. 2018;32(1):102-110. doi:10.1038/leu.2017.179

5. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. *Blood*. 2003;101(11): 4569-4575. doi:10.1182/blood-2002-10-3017

6. Cohen YC, Saranga A, Gatt ME, et al. Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective study. *Am J Hematol*. 2018;93(6):810-815. doi:10.1002/ajh.25098

7. Bourdon JC, Fernandes K, Murray-Zmijewski F, et al. p53 isoforms can regulate p53 transcriptional activity. *Genes Dev*. 2005;19(18): 2122-2137. doi:10.1101/gad.1339905

8. Surget S, Khoury MP, Bourdon JC. Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. *Onco Targets Ther*. 2013;7:57-68. doi:10.2147/OTT.S53876

9. Hafner A, Bulyk ML, Jambhekar A, Lahav G. The multiple mechanisms that regulate p53 activity and cell fate. *Nat Rev Mol Cell Biol*. 2019; 20(4):199-210. doi:10.1038/s41580-019-0110-x

10. Joruiz SM, Bourdon JC. p53 Isoforms: Key Regulators of the Cell Fate Decision. *Cold Spring Harb Perspect Med*. 2016;6(8):a026039. doi: 10.1101/cshperspect.a026039

11. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. *FEBS Lett*. 1997;420(1):25-27. doi:10.1016/s0014-5793(97)01480-4

12. Xiong W, Wu X, Starnes S, et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. *Blood*. 2008;112(10):4235-4246. doi:10.1182/blood-2007-10-119123

13. Chang H, Yeung J, Qi C, Xu W. Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma. *Br J Haematol*. 2007; 138(3):324-329. doi:10.1111/j.1365-2141.2007.06649.x

14. Bourdon JC, Khoury MP, Diot A, et al. p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients. *Breast Cancer Res*. 2011;13(1):R7. doi:10.1186/bcr2811

15. Anensen N, Oyan AM, Bourdon JC, Kalland KH, Bruserud O, Gjertsen BT. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. *Clin Cancer Res*. 2006;12(13):3985-3992. doi:10.1158/1078-0432.CCR-05-1970

16. Boldrup L, Bourdon JC, Coates PJ, Sjöström B, Nylander K. Expression of p53 isoforms in squamous cell carcinoma of the head and neck. *Eur J Cancer*. 2007;43(3):617-623. doi:10.1016/j.ejca.2006.10.019

17. Rosiñol L, Oriol A, Rios R, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. *Blood*. 2019;134(16):1337-1345. doi:10.1182/blood.2019000241

18. Misiewicz-Krzeminska I, de Ramón C, Corchete LA, et al. Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma. *Blood Adv*. 2020;4(23): 6023-6033. doi:10.1182/bloodadvances.2020002711

19. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncol*. 2014;15(12):e538-e548. doi:10.1016/S1470-2045(14)70442-5

20. Misiewicz-Krzeminska I, Corchete LA, Rojas EA, et al. A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility. *Haematologica*. 2018;103(5): 880-889. doi:10.3324/haematol.2017.181628

21. Misiewicz-Krzeminska I, Isidro I, Gutiérrez N. Capillary nano-immunoassay for quantification of proteins from CD138-purified myeloma cells. *Bio Protocol*. 2019;9(12). doi:10.21769/BioProtoc.3267

22. Loughery J, Cox M, Smith LM, Meek DW. Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters. *Nucleic Acids Res*. 2014;42(12):7666-7680. doi:10.1093/nar/gku501

23. Khoury MP, Marcel V, Fernandes K, Diot A, Lane DP, Bourdon JC. Detecting and quantifying p53 isoforms at mRNA level in cell lines and tissues. *Methods Mol Biol*. 2013;962:1-14. doi:10.1007/978-1-62703-236-0_1

24. Laptenko O, Prives C. Transcriptional regulation by p53: one protein, many possibilities. *Cell Death Differ*. 2006;13(6):951-961. doi:10.1038/sj.cdd.4401916

25. Harms KL, Chen X. The functional domains in p53 family proteins exhibit both common and distinct properties. *Cell Death Differ*. 2006; 13(6):890-897. doi:10.1038/sj.cdd.4401904

26. Fujita K, Mondal AM, Horikawa I, et al. p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. *Nat Cell Biol*. 2009;11(9):1135-1142. doi:10.1038/ncb1928

27. Gadea G, Arsic N, Fernandes K, et al. TP53 drives invasion through expression of its Δ133p53β variant. *Elife*. 2016;5:e14734. doi:10.7554/eLife.14734

28. Hofstetter G, Berger A, Schuster E, et al. Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer. *Br J Cancer*. 2011;105(10):1593-1599. doi:10.1038/bjc.2011.433

29. Nutthasirikul N, Limpaiboon T, Leelayuwat C, Patrakitkomjorn S, Jearanaikoon P. Ratio disruption of the Δ133p53 and TAp53 isoform equilibrium correlates with poor clinical outcome in intrahepatic cholangiocarcinoma. *Int J Oncol*. 2013;42(4):1181-1188. doi:10.3892/ijo.2013.1818

30. Nutthasirikul N, Hahnvajanawong C, Techasen A, et al. Targeting the Δ133p53 isoform can restore chemosensitivity in 5-fluorouracil-resistant cholangiocarcinoma cells. *Int J Oncol*. 2015;47(6):2153-2164. doi:10.3892/ijo.2015.3188

31. Bischof K, Knappskog S, Hjelle SM, et al. Influence of p53 isoform expression on survival in high-grade serous ovarian cancers. *Sci Rep*. 2019;9(1):5244. doi:10.1038/s41598-019-41706-z

32. Ozretić P, Hanžić N, Proust B, et al. Expression profiles of p53/p73, NME and GLI families in metastatic melanoma tissue and cell lines. *Sci Rep*. 2019;9(1):12470. doi:10.1038/s41598-019-48882-y

33. Kazantseva M, Mehta S, Eiholzer RA, et al. The Δ133p53β isoform promotes an immunosuppressive environment leading to aggressive prostate cancer. *Cell Death Dis*. 2019;10(9):631. doi:10.1038/s41419-019-1861-1

34. Guo Y, Rall-Scharpf M, Bourdon JC, Wiesmüller L, Biber S. p53 isoforms differentially impact on the POLι dependent DNA damage tolerance pathway. *Cell Death Dis*. 2021;12(10):941. doi:10.1038/s41419-021-04224-3

35. Haaland I, Hjelle SM, Reikvam H, et al. p53 protein isoform profiles in AML: correlation with distinct differentiation stages and response to epigenetic differentiation therapy. *Cells*. 2021;10(4):833. doi:10.3390/cells10040833

36. Bischof K, Knappskog S, Stefansson I, et al. High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma. *BMC Cancer*. 2018;18(1):684. doi:10.1186/s12885-018-4591-3

37. Avery-Kiejda KA, Morten B, Wong-Brown MW, Mathe A, Scott RJ. The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome. *Carcinogenesis*. 2014; 35(3):586-596. doi:10.1093/carcin/bgt411

38. Courtois S, Verhaegh G, North S, et al. DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. *Oncogene*. 2002;21(44):6722-6728. doi:10.1038/sj.onc.1205874

39. Avery-Kiejda KA, Zhang XD, Adams LJ, et al. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. *Clin Cancer Res*. 2008; 14(6):1659-1668. doi:10.1158/1078-0432.CCR-07-1422

40. Oh L, Hainaut P, Blanchet S, Ariffin H. Expression of p53 N-terminal isoforms in B-cell precursor acute lymphoblastic leukemia and its correlation with clinicopathological profiles. *BMC Cancer*. 2020;20(1): 110. doi:10.1186/s12885-020-6599-8

41. Marcel V, Fernandes K, Terrier O, Lane DP, Bourdon JC. Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response. *Cell Death Differ*. 2014;21(9): 1377-1387. doi:10.1038/cdd.2014.73

42. Silden E, Hjelle SM, Wergeland L, et al. Expression of TP53 isoforms p53β or p53γ enhances chemosensitivity in TP53(null) cell lines. *PLoS One*. 2013;8(2):e56276. doi:10.1371/journal.pone.0056276

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.